Calif. Supreme Court Rules In Favor Of Glaxo, FDA On Prop 65 Warnings
This article was originally published in The Rose Sheet
Executive Summary
State regulations that conflict with FDA drug labeling are preempted by federal law, the California Supreme Court ruled April 15 in a case challenging the state's mandatory Prop 65 warning requirements for nicotine replacement therapy (NRT) products